Cost Minimization and Budget Impact Analysis of Pneumococcal Conjugated Vaccines in 3 Latin American Countries (2020-2024)
Author(s)
Gómez J1, Moreno LE2, Constenla DO3, Loggia V1, Petrozzi V4
1GSK, Victoria, B, Argentina, 2GSK, Bogota, B, Colombia, 3GSK, Panama, MD, Panama, 4GSK, Lima, Peru
OBJECTIVES: Countries in Latin America (LAC) introduced infant Pneumococcal Conjugated Vaccine (PCVs) immunization in their National Immunization Programs (NIPs) following the recommendation of the World Health Organization (WHO). Based on systematic literature reviews and expert opinions, WHO stated there is no evidence of a difference in the net impact of PCVs on overall disease burden, leaving concerns regarding the PCV choice. Therefore, we conducted a budget impact (BI) analysis of the use of PCV10 and PCV13 in Paraguay, Peru and Colombia to address the question of affordability. METHODS: An excel-based cost calculator was used to estimate the BI of PCVs use in these countries between 2020 and 2024. We compared direct medical cost of the base case scenario (no-vaccine) with the post-vaccine introduction scenario to calculate the BI from the perspective of health care system. In addition, the BI comparing the use of PCV13 and PCV10 was also included. Vaccine prices and vaccine effects were obtained from published data of international organizations. RESULTS: The 5-years BI for PCV10 in Paraguay, Peru and Colombia was -33.3, 83.8 and 100.1 million of United States dollars (USD), respectively, and an incremental BI for PCV13 of 4.9, 14.8 and 21.4 million USD, respectively when compared with PCV10. The use of PCV10 in the NIP of Paraguay, Peru and Colombia will save 70.3, 31.8 and 46.1 million USD respectively in direct medical costs. CONCLUSIONS: The analysis found significant differences in the 5-years BI between PCV10 and PCV13, with more than 9 million USD incremental savings on treatments costs and 31.8 million USD incremental savings in vaccine costs for PCV10, in the analyzed countries. These findings can be used in budget planning and to maximize NIP budget. However, to sustain universal mass vaccination programs, policymakers should carefully consider the broader interaction among vaccines and socio-economic development.
Conference/Value in Health Info
2020-11, ISPOR Europe 2020, Milan, Italy
Value in Health, Volume 23, Issue S2 (December 2020)
Code
PIN13
Topic
Economic Evaluation, Epidemiology & Public Health, Health Policy & Regulatory, Methodological & Statistical Research
Topic Subcategory
Budget Impact Analysis, Public Health, Public Spending & National Health Expenditures
Disease
Pediatrics, Vaccines